Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.35 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10604319 | 0.94 | ACE2 (0.44) | CA1SLC1A2SLC1A1ACE2GPR84 | |
| SCHEMBL2147213 | 0.92 | ACE2 (0.47) | CA1ACE2GPR84FFAR1MAPT | |
| SCHEMBL28936397 | 0.87 | CHRM1 (0.41) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL29265240 | 0.82 | ACE2 (0.44) | CA2CA1SLC1A2SLC1A1ACE2 | |
| SCHEMBL27644528 | 0.82 | CA2 (0.45) | CA2MAPK1CA1SLC1A3SLC1A2 | |
| Pivalate SCHEMBL5573309 | 0.80 | CA2 (0.44) | CA2MAPK1CA1SLC1A3SLC1A2 | |
| SCHEMBL7387346 | 0.78 | CYP1A2 (0.35) | SLC1A3SLC1A2SLC1A1 | |
| Acetic Acid SCHEMBL5574282 | 0.78 | CA2 (0.45) | CA2MAPK1CA1SLC1A3SLC1A2 | |
| SCHEMBL28657658 | 0.77 | CA2 (0.48) | CA2MAPK1CA1SLC1A3SLC1A2 | |
| SCHEMBL3745224 | 0.77 | CA2 (0.48) | CA2MAPK1CA1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2018-12-06 | — | — | US | disclosed |
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2016-10-13 | — | — | US | disclosed |
| US-9345739-B2 | Methods and compositions for the treatment of proteinuric diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-7759302-B2 | Octapeptides: Arg-X-Asp-Leu-Asp-Ser-Leu-Arg where X is a 2-aminoaulfonylaminoalkanoic acid and optionally having various end groups; biologically active as ligands of blood platelet integrin GPIIbIIIa and the alpha v integrins | MERCK PATENT GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-20060148716-A1 | Peptidic sulfonamides | MERCK PATENT GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | CA2 1281/4885MAPK1 4243/4885CA1 3674/4885 |
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | CA2 1281/4885MAPK1 4243/4885CA1 3674/4885 |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | ITGB3, PLAUR, PROC | CA2 1281/4885MAPK1 4243/4885CA1 3674/4885 |
| US-20060148716-A1 | Peptidic sulfonamides | ITGB3, ITGA2B, ITGA2 | CA2 1978/4885MAPK1 4034/4885CA1 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.